<DOC>
	<DOCNO>NCT01563029</DOCNO>
	<brief_summary>This Phase IIb , multi-centre , stratify , randomise , double-blind , double-dummy , parallel-group , placebo active control study child age 5-11 year persistent uncontrolled asthma . Subjects meet inclusion criterion none exclusion criterion screen visit ( Visit 1 ) enter four week run-in period time continue current medication . Visit 2 occur two week run-in period allow review compliance daily diary run-in medication . At Visit 3 ( end run-in/randomization visit ) , subject meet eligibility criterion remain uncontrolled despite baseline therapy stratify base pre screen inhale corticosteroid ( ICS ) use . Once stratify , subject randomise treatment phase study receive one five treatment 12 week . Approx 1200 subject age 5 11 screen achieve 575 randomize total 115 randomized/evaluable subject per treatment arm . Subjects attend on-treatment visit 2 , 4 , 8 12 week ( Visits 4 , 5 , 6 7 respectively ) . A follow-up contact perform one week complete study medication . All subject must attempt spirometry measurement Visits 1 3 . For subject , time 24-hour urine collection urinary cortisol creatinine excretion perform prior randomization Visit 2 within 7 day prior Visit 7 . All subject must perform PEF daily visit 1 7 . The primary endpoint change baseline pre-dose ( i.e . dose trough ) PM PEF patient hand hold electronic daily diary Endpoint ( Endpoint define mean last 7 day treatment ) . Safety assessment include adverse event , oropharyngeal examination , clinical chemistry , urinary cortisol , vital sign .</brief_summary>
	<brief_title>A Dose-ranging Study Fluticasone Furoate ( FF )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Written inform consent least one parent/ legal guardian take part study . : Diagnosis asthma prebronchodilator PEF ≥50 % ≤90 % best postbronchodilator value Receiving therapy short act betaagonist ( SABA ) alone , LTM , ICS ( total daily dose &lt; FP 200mcg equivalent ) Exclusion : history lifethreatening asthma history asthma exacerbation asthma within 6 month prior screen . Culturedocumented suspected bacterial viral infection significant abnormality medical condition Present use tobacco product</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>